We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
+41.22%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$51.2M
Cap. Flow
+$23.3M
Cap. Flow %
13.57%
Top 10 Hldgs %
82.87%
Holding
37
New
3
Increased
5
Reduced
1
Closed
9

Top Buys

Rank Stock Value
1
HIGH icon
Simplify Enhanced Income ETF
HIGH
+$33.7M
2
ACHV icon
Achieve Life Sciences
ACHV
+$10.9M
3
AKRO
Akero Therapeutics
AKRO
+$5.47M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.63M
5
APLT
Applied Therapeutics
APLT
+$3.31M

Top Sells

Rank Stock Value
1
PAGP icon
Plains GP Holdings
PAGP
+$21.9M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.87M
3
BSV icon
Vanguard Short-Term Bond ETF
BSV
+$2.13M
4
IBDP
iShares iBonds Dec 2024 Term Corporate ETF
IBDP
+$2.13M
5
SPSB icon
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
+$1.36M

Sector Composition

Rank Sector Weight
1 Healthcare 79.77%
2 Miscellaneous 18.77%
3 Technology 1.46%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLT
1
DELISTED
Applied Therapeutics
APLT
$41.6M 24.19%
6,111,906
+736,924
+14% +$3.31M
HIGH icon
2
Simplify Enhanced Income ETF
HIGH
$64.1M
$28M 16.29%
1,492,581
+1,372,360
+1,142% +$33.7M
TCRX icon
3
TScan Therapeutics
TCRX
$51.1M
$16.6M 9.65%
2,087,139
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.3B
$11.5M 6.69%
43,032
+13,000
+43% +$3.06M
ACHV icon
5
Achieve Life Sciences
ACHV
$834M
$11.1M 6.49%
+2,453,092
New +$10.9M
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$743M
$9.24M 5.38%
869,927
+426,880
+96% +$3.63M
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$8.28M 4.82%
327,752
+227,700
+228% +$5.47M
FULC icon
8
Fulcrum Therapeutics
FULC
$294M
$7.08M 4.12%
750,000
– –
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$4.56M 2.65%
178,500
– –
DAWN
10
DELISTED
Day One Biopharmaceuticals
DAWN
$4.47M 2.6%
270,664
– –
ARDX icon
11
Ardelyx
ARDX
$984M
$4.34M 2.52%
594,174
– –
LONA
12
LeonaBio Inc
LONA
$74.8M
$4.09M 2.38%
149,279
– –
KURA icon
13
Kura Oncology
KURA
$1.13B
$2.77M 1.61%
130,000
– –
TSAT icon
14
Telesat
TSAT
$652M
$2.5M 1.46%
290,781
– –
KYMR icon
15
Kymera Therapeutics
KYMR
$9.82B
$2.27M 1.32%
56,359
– –
MBB icon
16
iShares MBS ETF
MBB
$39B
$2.07M 1.21%
22,400
– –
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.74B
$1.98M 1.15%
+83,259
New +$1.86M
MIRM icon
18
Mirum Pharmaceuticals
MIRM
$5.94B
$1.76M 1.02%
70,000
– –
MRNS
19
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.63M 0.95%
180,100
– –
KYN icon
20
Kayne Anderson Energy Infrastructure Fund
KYN
$2.51B
$1.47M 0.86%
147,033
– –
STRO icon
21
Sutro Biopharma
STRO
$339M
$1.1M 0.64%
19,500
– –
TRVI icon
22
Trevi Therapeutics
TRVI
$2.39B
$897K 0.52%
+260,000
New +$580K
XFOR icon
23
X4 Pharmaceuticals
XFOR
$401M
$744K 0.43%
17,833
– –
EIGR
24
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$732K 0.43%
146,381
– –
LQD icon
25
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$32.9B
$485K 0.28%
4,456
– –
1
2

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
LKWM
Lee-Kelleher Wealth Management Fulton, Maryland $191M AUM 28.48% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
AA
Atmos Advisory Pittsburgh, Pennsylvania $191M AUM 12.84% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return

Propel Bio Management's Q1 2024 Portfolio in Review

As of Q1 2024, Propel Bio Management held 37 positions worth $172M, up 42% from $121M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Propel Bio Management deployed $23.3M of net new capital in Q1 2024, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Achieve Life Sciences: 2,453,092 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 64% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the most notable exit was Plains GP Holdings, an estimated $21.9M sold.

  • Propel Bio Management's largest Q1 2024 buy was Achieve Life Sciences: 2,453,092 shares worth $11.1M.
  • Propel Bio Management added most to Simplify Enhanced Income ETF in Q1 2024, an estimated $33.7M increase.
  • Propel Bio Management fully exited Plains GP Holdings in Q1 2024, selling an estimated $21.9M.
  • Propel Bio Management's ten largest holdings make up 83% of its $172M portfolio in Q1 2024.
  • Propel Bio Management opened 3 new positions and closed 9 in Q1 2024.
  • Propel Bio Management's portfolio value rose 42% quarter-over-quarter to $172M.

Based on Propel Bio Management's 13F filing for Q1 2024, filed 13 May 2024.